XL184 is a small-molecule kinase inhibitor recently included in first-line systemic therapy for patients with advanced, progressive medullary thyroid cancer (MTC). EF24 is a curcumin analog with a high bioavailability, and ZSTK474 is an inhibitor of the phosphatidylinositol 3-kinase signaling pathway. We investigated the effect of these compounds, alone and in combination, in two rearranged during transfection (RET)-mutated TT and MZ-CRC-1 MTC cell lines and in six mostly RET wild-type human MTC primary cultures. Low IC50 values demonstrated the efficacy of the drugs, whereas the combination index revealed an important synergistic effect of combinations of XL184 + ZSTK474 and XL184 + EF24. Cell-cycle changes and the induction of apoptosis or necrosis were modulated by single compounds or combinations thereof. Both XL184 and EF24, alone or combined, were effective in reducing calcitonin secretion. Western blot and in-cell Western analysis showed that the compounds prompted a decrease in general reactivity to phosphorylated antibodies. Our data confirm XL184 alone as the reference drug for RET-mutated MTC, but we also demonstrated that EF24 alone is effective in inhibiting MTC cell viability. We tested the combinations XL184 + ZSTK474 and XL184 + EF24 too, finding that they act synergistically, irrespective of RET mutation status. (Endocrinology 159: 2348(Endocrinology 159: -2360(Endocrinology 159: , 2018 M edullary thyroid cancer (MTC) is a rare neuroendocrine tumor that arises from the parafollicular C cells. According to current Surveillance, Epidemiology, and End Results Program data, it accounts for 1% to 2% of all thyroid cancers in the United States (1). The main secretory product of the parafollicular cells in MTC is calcitonin (CT), which is therefore the reference tumor marker for this neoplasm (2). MTC generally has a more aggressive biological behavior than the welldifferentiated papillary and follicular histotypes, and 30% of patients have distant metastases already at the time of their diagnosis. Primary treatment usually includes radical excision of the thyroid with central neck lymph node dissection. Alternative treatment modalities are often needed, however, particularly in patients with distant metastases, and cytotoxic chemotherapy and radiation therapy have proven scarcely effective (3).
M edullary thyroid cancer (MTC) is a rare neuroendocrine tumor that arises from the parafollicular C cells. According to current Surveillance, Epidemiology, and End Results Program data, it accounts for 1% to 2% of all thyroid cancers in the United States (1) . The main secretory product of the parafollicular cells in MTC is calcitonin (CT), which is therefore the reference tumor marker for this neoplasm (2) . MTC generally has a more aggressive biological behavior than the welldifferentiated papillary and follicular histotypes, and 30% of patients have distant metastases already at the time of their diagnosis. Primary treatment usually includes radical excision of the thyroid with central neck lymph node dissection. Alternative treatment modalities are often needed, however, particularly in patients with distant metastases, and cytotoxic chemotherapy and radiation therapy have proven scarcely effective (3) .
From a molecular standpoint, dominant-activating mutations in the rearranged during transfection (RET) proto-oncogene have been shown to have a crucial role in the development of MTC, in both familial and sporadic cases. The RET proto-oncogene is located on chromosome 10q11.2 and codes for a transmembrane receptor that has a tyrosine kinase (TK) activity. TKs are enzymes responsible for controlling mitogenic signals via the phosphorylation/dephosphorylation of many intracellular proteins involved in the signal transduction cascade. RET downstream signaling networks have a key role in regulating cell survival, differentiation, proliferation, migration, and chemotaxis (4) . Following RET-activating point mutations, the rat sarcoma (Ras)/rapidly accelerated fibrosarcoma (Raf)/MAPK kinase/ERK and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/ mammalian target of rapamycin (mTOR) signaling cascades are the most important pathways constitutively active in MTC and involved in tumorigenesis and disease progression (5) . The enhanced catalytic activity responsible for uncontrolled cell growth provides the molecular rationale for using a novel class of chemical compounds with a TK-inhibiting activity (TK inhibitors) in this type of cancer.
The new compound XL184 (better known as cabozantinib) has recently been investigated for use in the treatment of patients with unresectable, locally advanced or metastatic MTC in phase 3 trials (ClinicalTrials.gov identifier NCT01908426). XL184 is a small-molecule kinase inhibitor with potent activity against several TK receptors, such as tyrosine-protein kinase Met (cMET), vascular endothelial growth factor receptor 2 (VEGFR2), and RET (6) . Positive results obtained with cabozantinib (Cometriq; Exelixis, San Francisco, CA), in terms of safety and efficacy, led to its approval by the US Food and Drug Administration in 2012 and by the European Medicines Agency in 2014 for the treatment of patients with progressive, metastatic MTC (7) .
ZSTK474 is an ATP-competitive inhibitor of PI3K (8) . In a previous study, we showed that combined with a BRAF kinase inhibitor, ZSTK474 increases the efficacy of treatment in preclinical models of MTC and notably in the TT cell line (9) .
Natural products, such as curcumin, have recently played an important part in the discovery and development of new anticancer agents, and 49% of anticancer drugs introduced from the ;1940s until the end of 2014 were either natural products or directly derived from them (10) . Curcumin is a naturally occurring phytochemical from Curcuma longa, which has long been used in traditional Chinese and Indian herbal medicine. In vitro and in vivo studies have demonstrated the antiproliferative, anti-inflammatory, apoptosis-inducing, and antitumor properties of curcumin in a variety of cancer types (11) . Its low bioavailability has led to the development of the curcumin analog EF24, a diphenyl difluoroketone with similar safety profiles but enhanced anticancer activity and solubility. EF24 has exhibited anticancer activity in colon and gastric cancer, but no information is available, as yet, on its effect in MTC (12) .
The aim of our study was thus to investigate the efficacy of XL184, ZSTK474, and EF24, alone and in combination, in two reference cancer cell lines for MTC, i.e., TT cells carrying a RET C634W mutation and MZ-CRC-1 cells carrying a RET M918T mutation. We analyzed the effects of these compounds in six human primary thyroid cell cultures isolated from patients undergoing total thyroidectomy for MTC.
Materials and Methods

Cell and primary cultures
The TT cell line (catalog no. CRL-1803; RRID: CVCL_ 1774) was obtained from American Type Culture Collection-LGC Standards S.r.l. (Milan, Italy). The MZ-CRC-1 cell line (RRID: CVCL_A656) was obtained from Dr. Alessandro Antonelli (Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy). Both were cultured in RPMI 1640 (Gibco Life Technologies, Carlsbad, CA), supplemented with 10% fetal bovine serum, 2 mM L-glutamine (SigmaAldrich, Milan, Italy), and penicillin/streptomycin, as described elsewhere (13) . For primary cultures, tumor specimens were obtained from six patients (four women and two men; mean age 66 6 13 years) who underwent total thyroidectomy for MTC. The study was approved by our local Ethics Committee (protocol no. 12667-2016), and all patients gave their written, informed consent. The diagnosis of MTC was histologically confirmed on a portion of the same specimen as was used to prepare the primary culture. Samples were placed in culture medium (DMEM-F12; Gibco Life Technologies), supplemented with 10% fetal bovine serum (Gibco Life Technologies), 100 U/mL penicillin, and 100 g/mL streptomycin (Gibco Life Technologies), immediately after surgery and taken to our laboratory. They were washed twice with PBS (Gibco Life Technologies), cut into small pieces, and incubated in collagenase/dispase mix (Sigma-Aldrich) at 37°C for 60 minutes. The solution was filtered through a 100-mm cell strainer (BD Falcon; Becton Dickinson, Franklin Lakes, NJ) and centrifuged at 300g for 5 minutes. The sediment was then resuspended with culture medium and incubated at 37°C in 5% CO 2 in a humidified atmosphere. The medium was changed every 2 days thereafter. Cells between the second and third passage were used in the experiments.
Drugs
XL184 and ZSTK474 were purchased from Selleck Chemicals (Houston, TX). EF24 was purchased from SigmaAldrich. The powders were dissolved in a 10-mM stock solution in dimethyl sulfoxide, according to the manufacturer's instructions.
Mutation screening by direct sequencing
DNA was extracted from tissues after surgery using the DNeasy Blood and Tissue kit (Qiagen, Milan, Italy), according to the manufacturer's protocol. Mutation analyses were performed for RET (NM_020975.4; exons 5, 8, 10, 11, and 13-15) , N-RAS (NM_002524.3; exons 2 and 3), K-RAS (NM_ 033360.2; exons 2 and 3), and H-RAS (NM_005343.2; exons 2 and 3) by direct sequencing, as described in Mian et al. (14) and Pennelli et al. (15) . All patients gave their informed consent to genetic testing.
MTT cell viability assay
Cells were plated on 96-well tissue-culture microtiter plates at a density of 1 3 10 4 cells per well and treated with the drugs (XL184, ZSTK474, and EF24) at different concentrations (range 0.05 to 100 mM). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability (Sigma-Aldrich) was assayed after 72 hours of treatment, as described elsewhere (13) . For each drug, we obtained sigmoidal dose-response curve, and we measured the IC50 value, 50% of the maximum observed inhibitory effect on cell viability. Experiments were performed in triplicate and repeated three times.
Sulforhodamine B cell toxicology assay
Cells were plated on 96-well tissue-culture microtiter plates at a density of 1.5 3 10 4 cells per well and treated with the drugs, alone and in combination (XL184, ZSTK474, and EF24), at different concentrations (range 0.05 to 100 mM). The In Vitro Toxicology Assay Kit, sulforhodamine B (SRB)-based (Sigma-Aldrich) was assayed after 72 hours of treatment. Cells were fixed by gently layering one-fourth volume of cold 50% (w/v) trichloroacetic acid solution on top of the growth medium for 1 hour at 4°C. Plates were then rinsed with distilled water several times to remove trichloroacetic acid solution and air dried. Cells were stained with 0.4% SRB dye for 30 minutes and rinsed several times with the wash solution (1% acetic acid) until unincorporated dye was removed. Plates were air dried until no moisture was visible, and the incorporated dye was then dissolved at room temperature in a volume of solubilization solution (10 mM Tris), equal to the original volume of culture medium. After gentle stirring in a gyratory shaker, absorbance at a wavelength of 565 nm was spectrophotometrically measured, and sigmoidal dose-response curves were obtained for each drug. The resulting IC50 values were calculated. Experiments were performed in triplicate and repeated three times.
Determination of drug synergism
The combination index (CI) was calculated by using the MTT assay only and the CompuSyn 3.0.1 program [Ting-Chao Chou (Memorial Sloan Kettering Cancer Center, New York, NY) and Nick Martin (Massachusetts Institute of Technology, Cambridge, MA)]. Based on the mean MTT and SRB IC50 values, cells were treated with the inhibitors (alone or in combination) at a constant ratio for 72 hours, and a series of CI values was generated over a range of growth inhibition levels. The values at 50% growth inhibition are reported for all the tested combinations. Synergisms, additive effects, and antagonisms are defined as CI , 1, CI = 1, and CI . 1, respectively.
Trypan blue cell viability assay
The cytotoxic effects of XL184, ZSTK474, and EF24, alone and combined, were confirmed using the Trypan blue dye exclusion method. The assay was performed 72 hours after the treatment, using the mean IC50 doses determined by MTT and SRB assays, as described in Bertazza et al. (9) . Experiments were performed in triplicate and repeated three times.
Western blot analysis
TT and MZ-CRC-1 cells were treated for 4 hours in 60 mm cell-culture dishes using the mean MTT and SRB IC50 doses, with the compounds, alone and combined. Proteins were extracted and electroblotted onto nitrocellulose membranes, as described in Bertazza et al. (9) . The primary antibodies were anti-Erk1/2 (RRID: AB_390779), anti-phospho-Erk1/2 (RRID: AB_2315112), anti-Akt (RRID: AB_329827), anti-phospho-Akt (RRID: AB_329825), anti-VEGFR2 (RRID: AB_2212507), and anti-phospho-VEGFR2 (RRID: AB_2132355) (all from Cell Signaling Technology, Danvers, MA) and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; GeneTex, Irvine, CA; catalog no. GTX28245; RRID: AB_370675), all diluted 1:1000. All experiments were repeated three times.
In-cell Western analysis
Primary culture cells were plated on 96-well, flat, clearbottom, black polystyrene, tissue-culture microtiter plates at a density of 1 3 10 4 cells per well and treated with XL184, ZSTK474, and EF24, alone and in combination, at 10 mM concentrations for 4 hours. The cells were then fixed with cold 100% methanol for 10 minutes and washed twice with PBS. They were then blocked with 5% nonfat milk, diluted in PBS with 0.1% Tween 20 (TPBS; Sigma-Aldrich) for 1 hour, and incubated overnight at 4°C with the same primary antibodies, as described previously, all diluted 1:100 in TPBS 5% nonfat milk. The plates were washed five times with TPBS and then incubated for 1 hour with anti-mouse (Li-Cor Biosciences, Milan, Italy; catalog no. P/N 925-32210; RRID: AB_2687825) and anti-rabbit (Li-Cor Biosciences; catalog no. 925-68071; RRID: AB_2721181) 1:800 secondary IRDye antibodies. They were washed again five times with TPBS and scanned with the Odyssey CLX system (Li-Cor Biosciences) equipped with an infrared light technology for the signal detection. Signal intensity was quantified with Image Studio software (Version 4.0; Li-Cor), according to the manufacturer's instructions.
Wound-healing assay
Cells were seeded on six-well plates at 2 3 10 6 cells per well and treated for 48 hours with the drugs at one-half MTT IC50 doses. At the end of the treatment, the medium was removed and immediately replaced with complete culture medium, and a scratch wound was created using a pipette tip. Cell migration was then followed for the next 120 hours. Cells migrated into the wound surface, and the average distance of the migrating cells was measured under an inverted microscope (340) at 0 and 120 hours. The experiments were run in triplicate.
CT secretion
CT secretion was quantified in the conditioned medium after treating the cells with the drugs (alone and in combination) for 72 hours, as described in Bertazza et al. (9) . The experiments were run in triplicate for the TT and MZ-CRC-1 cells and once for the primary cultures.
Cell cycle and apoptosis
Cells were plated in 100 mm cell-culture dishes at a density of 2 3 10 6 cells and treated with the drugs, alone or combined, for 72 hours using the mean IC50 doses determined by MTT and SRB assays, as described elsewhere (13) . The cell-cycle analysis was done three times using the CytoFLEX flow cytometer, and data were analyzed with Kaluza flow cytometry analysis software (Beckman Coulter, Fullerton, CA). Apoptosis was assessed after 48 hours of treatment with the Annexin V-Fluorescein Isothiocyanate (FITC) Apoptosis Detection Kit (Bender MedSystems, Vienna, Austria) using the mean IC50 doses, as described in Barollo et al. (13) . The experiment was repeated three times.
Intracellular reactive oxygen species levels (DCFH-DA assay)
TT and MZ-CRC-1 cells (3 3 10 5 per well in a six-well plates) were incubated with EF24, XL184, and ZSTK474 and combinations thereof for 2 hours at near MTT IC50 doses. Thirty minutes before the end of the treatment, 2 0 ,7 0 -dichlorofluorescein diacetate (DCFH-DA; Sigma-Aldrich) was added to each sample at a final concentration of 5 mM. The cells were then harvested, and one-half of them was used for flow cytometry (CytoFLEX), whereas the fluorescence of the remaining cells was quantified with a plate reader (Victor-X3 multilabel counter; PerkinElmer, Turku, Finland).
Flow cytometry data were acquired and analyzed using the CytExpert software (Beckman Coulter). For oxidative stress induction as an internal control, cells were treated with 10 mM H 2 O 2 for 2 hours in complete medium (data not shown), and at least 10,000 events were collected for each sample. Experiments were performed in triplicate.
Statistical analysis
To determine if our data were normally distributed, the Kolmogorov-Smirnov, D'Agostino-Pearson, and Shapiro-Wilk tests were applied. To verify if two groups were significantly different, the two-tailed, independent samples t test was applied on normally distributed data. To compare more than two groups, the two-way ANOVA test was used, considering the measured, continuous variable as the dependent variable and the drugs and the patients as the two independent variables. Nonlinear regression and sigmoidal dose-response curves were used to calculate the IC50 values. All analyses were performed using MedCalc software, version 14.7 (MedCalc, Ostend, Belgium), or GraphPad Prism, version 5.03 for Windows (GraphPad Software, San Diego, CA). The significance level was set at P , 0.05 or P , 0.01.
Results
IC50 values and synergistic effects of XL184, ZSTK474, and EF24 in MZ-CRC-1 and TT cell lines
The effects of XL184, ZSTK474, and EF24 on MZ-CRC-1 and TT cell viability were examined in vitro. The IC50 values were ascertained 72 hours after treatment using MTT (Fig. 1A and 1B) and SRB ( Fig. 1C and 1D ) assays. All of the results are reported in Table 1 . XL184 was the drug most effective on MZ-CRC-1 cells, with the mean IC50 between the two methods used-1.4 mMwhereas for TT cells, it was ZSTK474 (mean IC50 = 1.42 mM). EF24 was similarly active in the two cell lines (mean IC50 = 4 mM for TT; mean IC50 = 6.55 mM for MZ-CRC-1). The drug synergy analysis was then performed using a wide range of doses and considering as the central one, the mean IC50 values derived from MTT and SRB dose-response curves. For the XL184 + ZSTK474 combination, we found a CI = 0.20 in TT cells and a CI = 0.15 in MZ-CRC-1 cells. For the XL184 + EF24 combination, we found a CI = 0.58 in TT cells and a CI = 0.31 in MZ-CRC-1 cells. The EF24 + ZSTK474 combination showed a near-additive effect in both cell lines (CI = 0.92 and CI = 0.81 for TT and MZ-CRC-1 cells, respectively). Trypan blue exclusion assay confirmed the effects on cell viability identified by the MTT and SRB assays, using single and combined mean IC50 doses (Fig. 1E) . After 72 hours, cells treated with XL184 showed a median viability of 55% and 56% for TT and MZ-CRC-1 cells, respectively. Cells treated with the curcumin analog, EF24, showed a median viability of 60% and 46% for TT and MZ-CRC-1 cells, respectively. ZSTK474 treatment alone caused a 53% and 55% drop in viability for TT and MZ-CRC-1 cells, respectively, compared with controls. The synergistic combination XL184 + ZSTK474 showed a viability reduction to 9% and 12% for TT and MZ-CRC-1 cells, respectively, whereas for the XL184 + EF24 combination, it was 32% and 26% for TT and MZ-CRC-1 cells, respectively. We also confirmed the near-additive effect of EF24 + ZSTK474, with a viability reduction to 52% and 45% for TT and MZ-CRC-1 cells, respectively.
Effects of the compounds on signaling pathways in the TT and MZ-CRC-1 cell lines
To ascertain the effects of the inhibitors on their targets, Western blot was used to test the separate and combined drugs on the VEGFR2, ERK, and Akt phosphorylation in the TT and MZ-CRC-1 cells (Fig. 2A) . Inhibition of the phosphorylation signals was quantified, as shown in Fig. 2B , and every drug or combination was compared with its own untreated control by t test, P , 0.05 or P , 0.01 (see Fig. 2 legend for details). At basal level, both cell lines expressed similar amounts of total VEGFR2, total Akt, and total ERK. We found phosphorylated VEGFR2 expressed in both untreated cell lines, whereas a significantly reduced reactivity was apparent on the phosphorylated receptor after XL184 treatment, either alone (43% for TT and 23% for MZ-CRC-1) or combined with EF24 (42% for TT and 58% for MZ-CRC-1); the XL184 + ZSTK474 combination only induced a significant reduction in the phosphorylated VEGFR2 signal in TT cells (17% viability compared with control). XL184 alone inhibited Akt phosphorylation in both cell lines (18% for TT and 43% for MZ-CRC-1) and so did ZSTK474 (30% for TT and 9% for MZ-CRC-1). EF24 was particularly effective in reducing the phosphorylated Akt signal in TT cells (41% of viability compared with control). The XL184 + ZSTK474 combination induced a significant reduction in Akt phosphorylation in both cell lines (19% for TT and 8% for MZ-CRC-1) and so did the ZSTK474 + EF24 combination (41% for TT and 13% for MZ-CRC-1), whereas the XL184 + EF24 combination was only effective in TT cells (61% of viability compared with control). The phosphorylated ERK signal was only inhibited in TT cells treated with XL184 (45% of viability compared with control), whereas the combination of cabozantinib with EF24 or ZSTK474 did not alter the effects of the latter two drugs alone (41% and 44%, respectively).
Cell-cycle distribution
We analyzed the effects of the compounds after 72 hours on the MZ-CRC-1 (Fig. 3A) and TT (Fig. 3B) cell-cycle distribution using the mean IC50 doses derived from MTT and SRB dose-response curves. XL184 and EF24 were the most effective single drugs, inducing a substantial (P , 0.05) increase in the sub-G1 phase in both cell lines, with a concomitant G0/G1-phase reduction (P , 0.05). ZSTK474 alone induced a less-marked increase in the sub-G1 phase, however significant, compared with the untreated control (P , 0.05). The XL184 + ZSTK474 combination was highly effective in inducing a remarkable increase in the sub-G1 phase, from 1% in untreated cells to 42% for MZ-CRC-1 (P , 0.01) and from 5% in untreated cells to 24% for TT cells (P , 0.01), with a concomitant decrease in the G0/G1 phase. The XL184 + EF24 combination prompted an increase in the sub-G1 phase, from 1% in untreated cells to 36% for MZ-CRC-1 (P , 0.01); in TT cells, this combination caused a sub-G1-phase increase, from 5% in untreated cells to 20% (P , 0.05) and also an increase in the G2/ M phase, from 35% in untreated cells to 54% (P , 0.05), with a concomitant reduction in the G0/G1 phase for both cell lines. For the ZSTK474 + EF24 combination, we noticed an increase (P , 0.05) in the sub-G1 phase for both cell lines. All data analyzed by t test compared with untreated control.
Apoptosis
Flow cytometry after Annexin V-FITC/propidium iodide staining was performed in the MZ-CRC-1 and TT cell lines treated with the drugs for 48 hours using the mean IC50 doses to discriminate between apoptosis and necrosis ( Table 2 ). The most relevant results are shown in Fig. 3C and 3D , where I-3 indicates live cells, I-4 early apoptosis, I-2 necrosis/late apoptosis, and I-1 dead cells. A significant increase in the degree of dead cells was seen in MZ-CRC-1 cells treated with XL184 alone (from 4% in control cells to 33%, P , 0.01) or combined with ZSTK474 (47%, P , 0.01). A significant increase was also visible for ZSTK474 (from 4% in control cells to 26%, P , 0.01) and EF24 (from 4% in control cells to 30%, P , 0.01), alone and combined (41% for XL184 + EF24 and 31% for ZSTK474 + EF24, both P , 0.01; Fig. 3C ). In TT cells, a significant increase in early apoptosis following EF24 treatment alone (from 1% in untreated cells to 13%, P , 0.01) and combined with ZSTK474 (14%, P , 0.01) was observed. A significant increase was also visible for the XL184 + ZSTK474 combination (from 1% in untreated cells to 13%, P , 0.01). A sustained increase in the proportion of dead/necrotic cells was apparent after treatment with the drugs alone, in particular, for XL184 and EF24, and combined (Fig. 3D ). All data analyzed by t test compared with its own control.
EF24 increases intracellular reactive oxygen species levels
We investigated whether the intracellular reactive oxygen species (ROS) levels in TT and MZ-CRC-1 cell lines could be altered by EF24, XL184, or ZSTK474. Treatment with EF24 or ZSTK474 alone significantly (t test, P , 0.05) increased intracellular ROS levels (compared with untreated controls, set as 100%) by 65% and 32%, respectively, in MZ-CRC-1 cell lines and by 29% and 38%, respectively, in TT cell lines. By contrast, XL184 alone prompted a 22% and 32% significant decrease (P , 0.05) in MZ-CRC-1 and TT cells, respectively ( Fig. 3E and 3F) . Treatment with ZSTK474, combined with EF24, significantly (P , 0.05) raised the intracellular ROS levels in both cell lines (by 91% and 35% for MZ-CRC-1 and TT cells, respectively). When XL184 was combined with EF24, however, the intracellular ROS levels significantly (P , 0.05) dropped in both cell lines (by 34% and 32% for the MZ-CRC-1 and TT cells, respectively).
Effects of compounds on CT secretion of MTC cell lines
Chemiluminescent immunoassay was used to examine the effects of the drugs on the CT levels in the culture medium. As shown in Fig. 4A , for both cell lines, the CT levels were significantly lower than in the control after 72 hours with XL184 or EF24 alone or with the ZSTK474 + EF24 or XL184 + ZSTK474 combinations (t test, P , 0.05). The XL184 + EF24 combination was only effective in reducing CT secretion in TT cells (P , 0.05). Treatment with ZSTK474 alone had no effect on CT secretion (compared with the control) in either cell line.
Effects of compounds on TT and MZ-CRC-1 migration
We performed an in vitro wound-healing assay to examine the effect of XL184, ZSTK474, and EF24 on TT and MZ-CRC-1 cell migration, a core process in tumor growth. After 120 hours of the end of treatment, migration of both cell lines was found significantly inhibited by XL184, alone or combined with EF24 and ZSTK474, when compared with the untreated cells (t test, P , 0.05; Fig. 4C and 4D) .
Effects of the compounds in primary cultures derived from MTC patients A RET somatic mutation was found in only one case (patient B.R.), located in exon 16 at codon 918 (M918T). TT cell line I-3 (live cells) 97% 6 9 69% 6 5 47% 6 4 43% 6 4 12% 6 2 29% 6 3 48% 6 5 I-4 (early apoptosis) 1% 6 1 6% 6 2 5% 6 2 13% 6 2 13% 6 1 7 %6 1 14% 6 5 I-2 (necrosis) 1% 6 1 12% 6 1 37% 6 5 17% 6 2 44% 6 4 42% 6 2 16% 6 1 I-1 (dead cells) 1% 6 1 13% 6 2 11% 6 2 27% 6 3 31% 6 3 22% 6 2 22% 6 3 Total 100% 100% 100% 100% 100% 100% 100% MZ-CRC-1 cell line I-3 (live cells) 93% 6 5 67% 6 4 65% 6 6 60% 6 6 42% 6 5 46% 6 3 55% 6 7 I-4 (early apoptosis No somatic mutations were found for the N-, H-, and K-RAS genes in any of the six patients analyzed. The effects of XL184, ZSTK474, and EF24, alone and in combination, were examined on primary cultures obtained from the six patients after they underwent total thyroidectomy for MTC. All of the CI values are presented in Table 3 . The analysis showed a synergistic effect for the XL184 + ZSTK474 and XL184 + EF24 combinations in all patients and particularly for the patient carrying the M918T RET mutation. Only a near-additive effect was observed for the combination ZSTK474 + EF24. As shown in Fig. 4B , the drugs significantly influenced CT secretion in primary cultures of patients (two-way ANOVA, P , 0.0001, F = 118.5).
In-cell Western (ICW) analysis was used to test the effects of the separate and combined compounds on the phosphorylation of VEGFR2, ERK, and Akt ( Fig. 2C-2F ). At basal level, all patients expressed similar amounts of total VEGFR2, total Akt, and total ERK. Phosphorylated VEGFR2 was expressed in all specimens, whereas there was a markedly reduced reactivity compared with the control after XL184 treatment, especially for the patient B.R. harboring the RET M918T mutation (P , 0.01). The XL184 + EF24 and XL184 + ZSTK474 combinations induced the same reduction in the phosphorylated VEGFR2 signal as XL184 alone, whereas the ZSTK474 + EF24 combination was only effective in patient M.I. (Fig. 2D) . The phosphorylated ERK signal was significantly (P , 0.05) inhibited in all samples treated with XL184, alone or combined with EF24 or ZSTK474, particularly in patient B.R. (P , 0.01; Fig. 2E ). ZSTK474 and EF24, separately and combined, prompted a significant reduction (P , 0.05) in the phosphorylated ERK signal (in 2:6, 4:6, and 4:6 patients, respectively; Fig. 2E ). ZSTK474 alone strongly inhibited Akt phosphorylation in all samples (P , 0.05), but when it was combined with EF24 or XL184, it only did so in 5:6 specimens (Fig. 2F ).
XL184 and EF24 alone were effective in 2:6 and 1:6 patients, respectively, whereas the combination of the two led to a significant reduction in Akt phosphorylation in 4:6 samples (P , 0.05; Fig. 2F ). All data analyzed by t test compared with untreated control.
Discussion
Radical surgery is currently the only curative treatment of MTC, although in patients who are not biochemically cured and even in those with proven distant metastases, the disease may take an indolent course with a slow rate of tumor progression and a good quality of life. There are currently no therapeutic options for such patients who are followed up with periodic CT/carcinoembryonic antigen measurements and imaging in an effort to identify disease sites potentially amenable to surgery. Some patients experience progressive disease, however, and in these cases, the first-line systemic therapy is currently based on the use of TK inhibitors (1) . Two such drugs-vandetanib and cabozantinib (also known as XL184)-were recently approved for use in patients with advanced progressive MTC (16) . A phase-3 trial showed that XL184 provided the greatest clinical benefit for patients with MTC carrying RET M918T or RAS mutations (17) . By acting on RET, XL184 may also inhibit the signaling pathways required for tumor cell proliferation and survival (i.e., by targeting oncogene addiction) in much the same way as other kinase inhibitors known to target driver oncogenes in specific tumors (18) . Along with such positive effects, XL184 has also been found capable of activating the hypoxiainducible factor pathway in hypoxic MTC cells, which may contribute to drug resistance by increasing the expression of downstream factors (19) . The need for long-standing treatment protocols, as a result of the drug's cytostatic effect; the far-from-negligible, adverse effects experienced by some patients; and the drug resistance mechanisms (that virtually all patients experience with time) remain unresolved issues. In this scenario, new, effective molecules or synergistic combinations that can overcome said problems are urgently awaited.
The current study demonstrated that ZSTK474 (a PI3K/Akt pathway inhibitor) and EF24 (a curcumin analog) enhance the anticancer activities of XL184, both in MTC cell lines and in primary cultures. Combinations of drugs were found more effective than single compounds, as emerged from our MTT, SRB, and Trypan blue cell-viability assays. Their greater efficacy is attributable, not only to their combined action on their specific molecular targets but also to particular effects exerted by some drugs, such as an increase in (20) . An increase in ROS is detrimental for cancer cell survival, inducing an oxidative stress with a potential negative impact on DNA, lipids, and proteins (21) . These effects already have been observed in numerous studies that reported that EF24 increased ROS production in different cancer cells (22) (23) (24) (25) (26) (27) . Based on these considerations, we have also measured ROS levels in our treated MTC cells, and it is noteworthy that EF24 increased the already-higher ROS levels, thereby exacerbating oxidative stress of TT and MZ-CRC-1. Interestingly also, ZSTK474 alone increased ROS levels in our cells, unlike what was found in another study present in the literature, by Gupta et al. (28) , where the PI3K inhibitor reduced ROS release in neutrophils derived from chronic obstructive pulmonary disease patients. This discrepancy is probably because neutrophils are nontumor cells, with nonaltered signaling pathways. Hence, our data can indicate that EF24 (with or without ZSTK474) exerts its most important role in ROS augmentation in both cell lines, underlining its strong effects almost independently to ZSTK474. We observed a decrease in ROS levels in both cell lines after XL184 treatment, alone or combined with EF24. We have not found in the literature studies directly explaining this behavior. In their recent work, Starenki et al. (29) show that XL184 is able to increase the mitochondrial membrane potential in TT and MZ-CRC-1 cells, and we can speculate that this finding could be related to the decrease of ROS levels in our model. The use of Western blot and ICW analysis brought to light important differences between the phosphorylation patterns of stable cell lines and primary cultures after their treatment. Such different behavior may be simply because of the fact that both cell lines had mutated RET, whereas our primary cultures were obtained from patients who, with one exception, carried a wild-type RET. Although the single and combined treatments were particularly effective in the patient harboring the RET M918T mutation, consistently with the report from Sherman et al. (17) , our data also showed that combination treatments achieved a greater reduction in phosphorylation signals in RET wild-type patients too. In particular, patients failing to respond to a single drug did respond to the combination treatment.
As for the effects on cell-cycle distribution and the induction of apoptosis, the XL184 + ZSTK474 combination again produced the most significant increase in the sub-G1 phase in both cell lines, corresponding to a significant increase in the fraction of dead cells, according to the Annexin V-FITC/propidium iodide test. Samadi et al. (30) used withanolides, a class of novel compounds that inhibit both RET kinase activity and the Akt/mTOR prosurvival pathway. As our XL184 + ZSTK474 combination blocks the same molecular pathways as withanolides, we might have expected similar results to those reported by Samadi et al. (30) . We attribute the different behavior seen in our study to the fact that XL184 is active, not only on RET but also on other TKs (cMET and VEGFR2), with different consequences on cell viability. The XL184 + EF24 combination also blocked the TT cells in the G2/M phase, without inducing apoptosis, a finding in line with a previous study by Zhao et al. (27) , in which EF24 alone had no effect in terms of inducing apoptosis in hepatocellular carcinoma cells. The same authors confirmed that the curcumin analog reduced the migratory potential of hepatocellular carcinoma cells, and we saw the same effect on TT and MZ-CRC-1 cells in cellcycle arrest, even though EF24 alone had no effect on cell migration.
A previous work by our group (9) demonstrated that a BRAF inhibitor (RAF265), alone or combined with ZSTK474, reduced CT production in supernatants of MTC TT cell lines by reducing the corresponding mRNA levels. In the present work, we confirmed that ZSTK474 alone had no effect on CT production in established MTC cell lines or primary cultures, and Faggiano et al. (31) had already reported that everolimus (a specific mTOR inhibitor) had no effect on CT production. The most interesting results of our study emerged after EF24 treatment, however; used alone, the curcumin analog was able to reduce CT levels significantly in TT and MZ-CRC-1 cells and in primary cultures, and combined with XL184, this inhibitory capacity was maintained in all primary cultures, even in the supernatants of RET wildtype patients. This may be a result of pleiotropic effects of the XL184 + EF24 combination, which needs to be clarified further.
In short, our data confirm that XL184 alone is the reference drug for RET-mutated MTC, but the absence of a complete response after monotherapies emphasizes the need for more active single agents or novel therapeutic combinations. We examined EF24, an analog of the natural plant turmeric (C. longa), in an in vitro model of MTC, finding that even alone, it is effective in inhibiting cell viability. We also tested the combinations XL184 + ZSTK474 and XL184 + EF24, finding that they can act synergistically on MTC cells, irrespective of the mutation status of patients. We believe that such combinations represent a potential therapeutic approach to MTC for RET wild-type patients or as a second-line pharmacological treatment, of all MTC patients.
